SCHEMBL40526

SCHEMBL40526

O=C(O)c1[nH]c2ccccc2c1-c1ccoc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.69
ALDH1A1 P00352 3/20 0.69
HPGD P15428 2/20 0.69
MAP2 P11137 2/20 0.54
GAA P10253 1/20 0.50
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
HTT P42858 1/20 0.49
GFER P55789 1/20 0.49
HSD17B10 Q99714 1/20 0.49
GPR35 Q9HC97 1/20 0.48
POLB P06746 1/20 0.46
MAP3K5 Q99683 1/20 0.46
MAPT P10636 1/20 0.45
TDO2 P48775 1/20 0.45
FOLH1 Q04609 1/20 0.44
TUBB4A P04350 1/20 0.44
TUBB P07437 1/20 0.44
TUBA3C P0DPH7 1/20 0.44
TUBA1B P68363 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3091466 0.82 KDM4E (1.00) KDM4EALDH1A1HPGDMAP2GAA
Hydrochloric Acid SCHEMBL5203951 0.81 KDM4E (0.96) KDM4EALDH1A1HPGDMAP2GAA
SCHEMBL39889 0.81 MAP2 (0.69) KDM4EALDH1A1HPGDMAP2MEN1
SCHEMBL39913 0.80 ALDH1A1 (0.55) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL30794843 0.77 KDM4E (0.66) KDM4EALDH1A1HPGDMAP2GAA
SCHEMBL9816507 0.76 KDM4E (0.79) KDM4EALDH1A1HPGDMAP2GAA
SCHEMBL9441674 0.76 KDM4E (0.79) KDM4EALDH1A1HPGDMAP2GAA
SCHEMBL7591935 0.76 KDM4E (0.79) KDM4EALDH1A1HPGDMAP2GAA
SCHEMBL19133599 0.75 KDM4E (0.62) KDM4EALDH1A1HPGDMAP2GAA
SCHEMBL7594894 0.75 KDM4E (0.71) KDM4EALDH1A1HPGDMAP2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2419408-A1 3-ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE MSD K.K. (JP) 2012-02-22 EP disclosed
US-20120028990-A1 3 ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE MSD K.K 2012-02-02 US disclosed
US-20120028990-A1 3 ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE MSD K.K 2012-02-02 US disclosed
US-20120028990-A1 3 ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE MSD K.K 2012-02-02 US disclosed
WO-2010119984-A1 3-ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-10-21 WO disclosed
WO-2010119984-A1 3-ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028990-A1 3 ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE IDO1, TPH1, AHR KDM4E 2947/4885ALDH1A1 2066/4885HPGD 719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.